BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 9028422)

  • 1. Mycophenolate mofetil: a unique immunosuppressive agent.
    Hood KA; Zarembski DG
    Am J Health Syst Pharm; 1997 Feb; 54(3):285-94. PubMed ID: 9028422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection.
    Simmons WD; Rayhill SC; Sollinger HW
    Drug Saf; 1997 Aug; 17(2):75-92. PubMed ID: 9285199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics of mycophenolate mofetil.
    Bullingham RE; Nicholls AJ; Kamm BR
    Clin Pharmacokinet; 1998 Jun; 34(6):429-55. PubMed ID: 9646007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation.
    Fulton B; Markham A
    Drugs; 1996 Feb; 51(2):278-98. PubMed ID: 8808168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enteric-coated mycophenolate sodium for transplant immunosuppression.
    Ingle GR; Shah T
    Am J Health Syst Pharm; 2005 Nov; 62(21):2252-9. PubMed ID: 16239415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individualization of mycophenolate mofetil dose in renal transplant recipients.
    van Hest RM; Hesselink DA; Vulto AG; Mathot RA; van Gelder T
    Expert Opin Pharmacother; 2006 Mar; 7(4):361-76. PubMed ID: 16503809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Mycophenolate mofetil--a new immunosuppressive agent].
    Bergan S; Albrechtsen D; Fauchald P
    Tidsskr Nor Laegeforen; 1996 Aug; 116(20):2439-41. PubMed ID: 8928103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.
    Staatz CE; Tett SE
    Clin Pharmacokinet; 2007; 46(1):13-58. PubMed ID: 17201457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443): initial clinical experience.
    Kirklin JK; Bourge RC; Naftel DC; Morrow WR; Deierhoi MH; Kauffman RS; White-Williams C; Nomberg RI; Holman WL; Smith DC
    J Heart Lung Transplant; 1994; 13(3):444-50. PubMed ID: 8061021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation.
    Hale MD; Nicholls AJ; Bullingham RE; Hené R; Hoitsma A; Squifflet JP; Weimar W; Vanrenterghem Y; Van de Woude FJ; Verpooten GA
    Clin Pharmacol Ther; 1998 Dec; 64(6):672-83. PubMed ID: 9871432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycophenolate mofetil (RS-61443): preclinical, clinical, and three-year experience in heart transplantation.
    Taylor DO; Ensley RD; Olsen SL; Dunn D; Renlund DG
    J Heart Lung Transplant; 1994; 13(4):571-82. PubMed ID: 7947873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mycophenolate mofetil, a possible new immunosuppresant].
    Weberová J; Voboril R; Semecký V
    Ceska Slov Farm; 2002 Sep; 51(5):220-5. PubMed ID: 12407919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rescue therapy with tacrolimus and mycophenolate mofetil does not prevent deterioration of graft function in C4d-positive chronic allograft nephropathy.
    Schwarz C; Regele H; Huttary N; Wahrmann M; Exner M; Nagy-Bojarsky K; Kletzmayr J; Hörl WH; Böhmig GA
    Wien Klin Wochenschr; 2006 Jul; 118(13-14):397-404. PubMed ID: 16865644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic impact and long-term graft outcomes of mycophenolate mofetil dosage modifications following gastrointestinal complications in renal transplant recipients.
    Machnicki G; Ricci JF; Brennan DC; Schnitzler MA
    Pharmacoeconomics; 2008; 26(11):951-67. PubMed ID: 18850764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycophenolate mofetil in kidney transplantation.
    Lui SL; Halloran PF
    Curr Opin Nephrol Hypertens; 1996 Nov; 5(6):508-13. PubMed ID: 8978998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of mycophenolic acid after enteric-coated mycophenolate versus mycophenolate mofetil in patients with progressive IgA nephritis.
    Czock D; Rasche FM; Carius A; Glander P; Budde K; Bauer S; Keller F; von Müller L
    J Clin Pharmacol; 2007 Jul; 47(7):850-9. PubMed ID: 17526858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolate mofetil.
    Sievers TM; Rossi SJ; Ghobrial RM; Arriola E; Nishimura P; Kawano M; Holt CD
    Pharmacotherapy; 1997; 17(6):1178-97. PubMed ID: 9399601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of mycophenolic acid in renal transplant recipients.
    van Hest RM; van Gelder T; Vulto AG; Mathot RA
    Clin Pharmacokinet; 2005; 44(10):1083-96. PubMed ID: 16176120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycophenolate mofetil: suggested guidelines for use in kidney transplantation.
    Behrend M
    BioDrugs; 2001; 15(1):37-53. PubMed ID: 11437674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolate mofetil: a review of its use in the management of solid organ transplantation.
    Bardsley-Elliot A; Noble S; Foster RH
    BioDrugs; 1999 Nov; 12(5):363-410. PubMed ID: 18031189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.